Cite
HARVARD Citation
Pavel, M. et al. (n.d.). Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 18 (10), pp. 1411-1422. [Online].